Clinical impact of first-line bevacizumab plus chemotherapy in metastatic colorectal cancer of mucinous histology: a multicenter, retrospective analysis on 685 patients.

Vincenzo CatalanoFrancesca BergamoChiara CremoliniBruno VincenziFrancesca NegriPaolo GiordaniPaolo AlessandroniRossana IntiniSilvia StragliottoDaniele RossiniBeatrice BorelliDaniele SantiniDonatella SartiMarco B L RocchiSara LonardiAlfredo FalconeVittorina ZagonelRodolfo MattioliFrancesco Graziano

Published in: Journal of cancer research and clinical oncology (2019)

Compared with NMC, MCRC patients with mucinous histology treated with bevacizumab plus chemotherapy had comparable OS despite lower overall response rate.

Keyphrases

metastatic colorectal cancer
end stage renal disease
newly diagnosed
low grade
ejection fraction
chronic kidney disease
locally advanced
prognostic factors
squamous cell carcinoma
clinical trial
cross sectional
rectal cancer
high grade